Prosecution Insights
Last updated: May 04, 2026
Application No. 18/360,944

ORGANOMETALLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME, AND ELECTRONIC APPARATUS INCLUDING THE ORGANIC LIGHT-EMITTING DEVICE

Non-Final OA §102
Filed
Jul 28, 2023
Priority
Jul 29, 2022 — RE 10-2022-0095043
Examiner
VAJDA, KRISTIN ANN
Art Unit
1622
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Samsung Electronics Co., Ltd.
OA Round
1 (Non-Final)
84%
Grant Probability
Favorable
1-2
OA Rounds
0m
Est. Remaining
95%
With Interview

Examiner Intelligence

Grants 84% — above average
84%
Career Allowance Rate
1333 granted / 1584 resolved
+24.2% vs TC avg
Moderate +10% lift
Without
With
+10.5%
Interview Lift
resolved cases with interview
Fast prosecutor
1y 9m
Avg Prosecution
38 currently pending
Career history
1622
Total Applications
across all art units

Statute-Specific Performance

§101
1.1%
-38.9% vs TC avg
§103
11.2%
-28.8% vs TC avg
§102
27.7%
-12.3% vs TC avg
§112
33.4%
-6.6% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1584 resolved cases

Office Action

§102
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Claims 1-20 are pending in the instant application. Claims 15-20 are withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to non-elected subject matter. The withdrawn subject matter is patentably distinct from the elected subject matter as it differs in structure and element and would require separate search considerations. In addition, a reference which anticipates one group would not render obvious the other. Claims 1, 2 and 4-13 are rejected. Claims 3 and 14 are objected. Information Disclosure Statements The information disclosure statements filed on March 5, 2024, December 30, 2024 and May 5, 2025 have been considered and signed copies of form 1449 are enclosed herewith. Election/Restrictions Applicant’s election without traverse of Group I, claims 1-14, in the response filed on October 6, 2025 is acknowledged. The restriction requirement is still deemed proper and is hereby made final. Applicant’s election without traverse of the species Compound 6 in the response filed on January 5, 2026 is acknowledged. Upon further search and consideration, however, the election of species requirement has been withdrawn (i.e., the full scope of the subject matter of claims 1-14 has been searched and examined in its entirety). Claim Rejections - 35 USC § 102 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. Claims 1, 2 and 4-13 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by JP 2016219490 A. JP 2016219490 A discloses compounds of the formula 2 PNG media_image1.png 164 168 media_image1.png Greyscale (see page 3), such as the compounds B-1, B-2, B-4, B-7, B-11, B-13, B-17, B-20, B-22, B-25, B-26, C-2, C-4, C-7, C-8, C-13, C-14, C- 17, C-20, C-26, E-1, E-5, E-11, F-2, F-4, F-8, F-10, F-13, F-17, F-23, G-4, and G-7 (see pages 41-50 and 55-62), which anticipate compounds of Formula 2-2 of the instant claims. Claim Objections Claims 3 and 14 are objected to for depending on a previous rejected claim. Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to KRISTIN ANN VAJDA whose telephone number is (571)270-5232. The examiner can normally be reached Mon-Fri 6:00-4:00. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, James Alstrum-Acevedo can be reached at 571-272-5548. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /KRISTIN A VAJDA/Primary Examiner, Art Unit 1622
Read full office action

Prosecution Timeline

Jul 28, 2023
Application Filed
Apr 21, 2026
Non-Final Rejection — §102 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12600712
AMINO-PYRIMIDINE AMIDES
3y 4m to grant Granted Apr 14, 2026
Patent 12600745
PROCESS FOR PREPARING B-[(7a, 1713)-17-HYDROXY-7-[9-[(4,4,5,5,5-PENTAFLUOROPENTYL)SULFINYL]NONYL]ESTRA-1,3,5(10)-TRIEN-3-YL]-BORONIC ACID
2y 7m to grant Granted Apr 14, 2026
Patent 12590094
COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE AND METABOLIC DISORDERS
4y 4m to grant Granted Mar 31, 2026
Patent 12590111
FLAVONOID DERIVATIVE FOR TREATING DENTAL CARIES
4y 1m to grant Granted Mar 31, 2026
Patent 12590093
INDOLO[2',3':3,4]PYRIDO[2,1-B]QUINAZOLINE COMPOUND AND USE THEREOF
3y 11m to grant Granted Mar 31, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
84%
Grant Probability
95%
With Interview (+10.5%)
1y 9m (~0m remaining)
Median Time to Grant
Low
PTA Risk
Based on 1584 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month